2. Cell Cycle/DNA Damage Autophagy
  3. Topoisomerase Autophagy
  4. Irinotecan hydrochloride

イリノテカン 塩酸塩  (Synonyms: Irinotecan (hydrochloride); (+)-Irinotecan (hydrochloride); CPT-11 (hydrochloride); VAL-413)

製品番号: HY-16562A 純度: 99.89%
COA 取扱説明書 Technical Support

Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 100286-90-6

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 86 在庫あり
Solution
10 mM * 1 mL in DMSO USD 86 在庫あり
Solid
50 mg $79 在庫あり
100 mg $119 在庫あり
200 mg $172 在庫あり
500 mg $343 在庫あり
1 g $580 在庫あり
5 g   お問い合わせ  
10 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 75 publication(s) in Google Scholar

Other Forms of Irinotecan hydrochloride:

イリノテカン 塩酸塩 関連抗体

Top Publications Citing Use of Products

顧客検証

Cell Proliferation/Viability Assay
In Vivo Efficacy Study
IHC
WB
Cell Imaging/Staining
IF

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693.  [Abstract]

    Analysis of drug sensitivity in various SW480 and HCT116 cell lines after 48 h of treatment with with Irinotecan (1 μmol/L).

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693.  [Abstract]

    Irinotecan (1 μmol/L, 48 h). Western blotting assays on caspase-3 and cleaved caspase-3 in SW480-Con/CBX3 cells following chemotherapy.

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693.  [Abstract]

    Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Immunohistochemical staining of tumor tissues with antibodies against Ki67, NRF2, and GPX2 (low-power view 100×, high-power view 400×, scale bar = 50 μm).

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693.  [Abstract]

    Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Tumors were measured every two days, and the tumor volumes were calculated. The tumors were excised and weighed 34 days after injection, and representative images of tumors were displayed (bar = 10 mm).

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693.  [Abstract]

    SW480-Con/CBX3 cells were treated with Irinotecan (1 μmol/L) for 8 h and stained with C11 BODIPY (oxidized lipid was stained green) and then detected by both flow cytometry and confocal microscopy. ERTracker Blue-White was used to detect the location of lipid oxidation by confocal microscopy (high-power view 400×, scale bar = 50 μm) (N = 3).

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692.

    Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Tumor volume in the control, CPT/5FU and E. copr groups were recorded daily.

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692.

    Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Expression of PCNA was measured by IHC and quantified by ImageJ in the tumor sections. Scale bar: 100 mm.

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2023 Apr 7;75(4):523-532.  [Abstract]

    Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 May 28;6(1):188.  [Abstract]

    Irinotecan (10 μM; 0–4 days). Cystine promoted colon cancer resistance to oxaliplatin and irinotecan (CPT-11) in vitro.

    Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Apoptosis. 2016 Feb;21(2):130-42.  [Abstract]

    (a) CPT-11 induces cell cycle arrest and apoptosis in RAW 264.7macrophages. a.Western blot analysis of cleaved caspase-3 and PARP levels. (b) CPT-11 induced cell cycle arrest and apoptosis in mouse peritoneal macrophages. Western blot analysis of cleaved caspase-3 and PARP levels in peritoneal macrophages isolated from vehicleand CPT-11-administered mice. (c) Caspase-3 inhibitor z-DEVD-fmk (ZD) attenuates CPT-11-induced loss of GATA6+ peritoneal macrophages in mice. Western blot analy

    Topoisomerase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    Topoisomerase Topo I Topo II DNA gyrase

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer[1].

    IC50 & Target[1]

    Topoisomerase I

     

    Cellular Effect
    Cell Line Type Value Description References
    Astrocyte IC50
    >10 μM
    Compound: Irinotecan HCl
    Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
    Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
    		[PMID: 26355532]
    HepG2 IC50
    0.95 μM
    Compound: Irinotecan hydrochloride
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 32081629]
    U-373MG ATCC IC50
    3.6 μM
    Compound: CPT-11, irinotecan
    Cytotoxicity against human U373MG cells expressing human intestinal carboxylesterase after 4 days in drug free medium by coulter counter
    Cytotoxicity against human U373MG cells expressing human intestinal carboxylesterase after 4 days in drug free medium by coulter counter
    		[PMID: 21733699]
    体外実験

    Irinotecan hydrochloride is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    イリノテカン 塩酸塩 関連抗体
    体内実験

    Irinotecan hydrochloride (CPT-11 hydrochloride, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    623.14

    分子式

    C33H39ClN4O6
    CAS 番号
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.[H]Cl
    Structure Classification
    Initial Source
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
    溶剤 & 溶解度
    体外: 

    DMSO : 125 mg/mL (200.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 3.33 mg/mL (5.34 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.6048 mL 8.0239 mL 16.0478 mL
    5 mM 0.3210 mL 1.6048 mL 3.2096 mL
    10 mM 0.1605 mL 0.8024 mL 1.6048 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 6 mg/mL (9.63 mM); Clear solution

      This protocol yields a clear solution of ≥ 6 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (60.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 6 mg/mL (9.63 mM); Clear solution

      This protocol yields a clear solution of ≥ 6 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (60.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 10 mg/mL (16.05 mM); Suspended solution; Need ultrasonic

    • Protocol 2

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: 10 mg/mL (16.05 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.89%

    COA (251 KB) HNMR (330 KB) LCMS (97 KB)

    取扱説明書 (2659 KB)
    参考文献
    細胞実験
    [2]

    Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    動物実験
    [1]

    Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 1.6048 mL 8.0239 mL 16.0478 mL 40.1194 mL
    5 mM 0.3210 mL 1.6048 mL 3.2096 mL 8.0239 mL
    DMSO 10 mM 0.1605 mL 0.8024 mL 1.6048 mL 4.0119 mL
    15 mM 0.1070 mL 0.5349 mL 1.0699 mL 2.6746 mL
    20 mM 0.0802 mL 0.4012 mL 0.8024 mL 2.0060 mL
    25 mM 0.0642 mL 0.3210 mL 0.6419 mL 1.6048 mL
    30 mM 0.0535 mL 0.2675 mL 0.5349 mL 1.3373 mL
    40 mM 0.0401 mL 0.2006 mL 0.4012 mL 1.0030 mL
    50 mM 0.0321 mL 0.1605 mL 0.3210 mL 0.8024 mL
    60 mM 0.0267 mL 0.1337 mL 0.2675 mL 0.6687 mL
    80 mM 0.0201 mL 0.1003 mL 0.2006 mL 0.5015 mL
    100 mM 0.0160 mL 0.0802 mL 0.1605 mL 0.4012 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Irinotecan hydrochloride Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Irinotecan100286-90-6(+)-IrinotecanCPT-11 VAL-413CPT11CPT 11VAL413VAL 413VAL-413TopoisomeraseAutophagyInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Irinotecan hydrochloride
    製品番号:
    HY-16562A
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.